1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

DCA and Avemar Show Clinical Promise Against (AML) Leukemia

A protocol for treating cancer using DCA (Dichloroacetate) and Avemar (a cancer fighting nutritional supplement) has shown clinical promise in treating the particularly pernicious AML Leukemia.

 
PRLog - May 25, 2012 - Several months ago I published a theoretical protocol for the treatment of cancer:

http://www.martincwiner.com/dca-and-avemar-a-theoretical-protocol-for-cancer/

Luckily for all of us, particularly those suffering from cancer, all of the chemicals/agents in the protocol have been previously approved by Health Canada (and the FDA) for use in humans.

While that’s good news for our ability to try the protocol, it’s horrible news for the necessary research to fully explore the protocol.  Given that DCA is not patentable and Avemar is a health food product, the pharmaceutical companies have zero interest in investing the millions it would take to run a full human trial.  (With the lack of patent protection, the pharmaceutical company would have no protection on its investment.)

The courageous health professionals at Medicor Cancer (http://www.medicorcancer.com/) were willing to try the protocol .  What happened is a pernicious form of Leukemia known as AML Leukemia in a given patient which was not responding to DCA alone, responded to the DCA-Avemar protocol.  There are other success stories with details to follow in further posts.

It has been known since the 1930’s that the ‘mitochondria’ in cells go dormant in cancer.  Mitochondria are similar to cellular turbochargers and produce the bulk of the energy requirements in human cells.  The fact that they go dormant in cancer is known as the ‘Warburg Hypothesis’.  In 2007, Dr Evangelos Michelakis at the University of Alberta discovered that a cheap, common laboratory chemical known as DCA (Dichloroacetate) was able to ‘wake up’ the dormant mitochondria.

As the result of a vestige of evolution it is the mitochondria, not the cell nucleus, which effects ‘apoptosis’ in cancer cells.  Most cells are able to detect that they are in a cancerous state and self destruct.  This process is called apoptosis.  DCA was able to awaken the dormant mitochondria and thus have the cells realize they were in a cancerous state and effect apoptosis.

As I researched further, I realized that cancerous cells had several more tricks up their sleeves.  They also dramatically increase a biochemical pathway called the Pentose-Phosphate shunt.  In healthy cells this pathway uses sugar to build DNA and some energy is also released.  In cancer cells this shunt is put into overdrive such that cancer cells can derive the energy they need.  I realized that while DCA may awaken the mitochondria, they may still be starving for sugar due to the overactive Pentose-Phosphate shunt.  Avemar selectively (meaning in cancerous cells only) reduces the speed of this pathway, starving the cancer cell for energy and more importantly, freeing sugar up for the now awakened mitochondria to function with.  With awakened mitochondria and sufficient sugar reaching them, they can effect apoptosis and end the cancer.  I conjectured that the two compounds together would prove an effective, broad spectrum, anti cancer protocol.

Avemar offers several other synergistic cancer fighting effects which are all discussed in the original video:

http://www.martincwiner.com/dca-and-avemar-a-theoretical-...

It is too early to release numbers and more case studies but it’s fair to say that the results are good thus far.  Stay tuned to this blog for further, more detailed releases.

The original release can be found here:
http://www.martincwiner.com/dca-and-avemar-show-clinical-...

--- End ---

Click to Share

Contact Email:
***@martincwiner.com Email Verified
Source:www.martincwiner.com
City/Town:Vaughan - Ontario - Canada
Industry:Biotech, Medical
Tags:leukemia, dca, aml, Avemar, cancer
Shortcut:prlog.org/11884938
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share